Biomaxima

Research Biomaxima (BMX) on Bullrun: valuation model: 85.4% overvalued, market cap PLN 39.83M, P/E 379.4. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerBMX
• ExchangeWAR
• CountryPoland
• SectorHealthcare
• IndustryDiagnostics & Research
• CurrencyPLN
• Valuation signal85.4% overvalued
• Market capPLN 39.83M
• P/E379.4
• Financial periodFY2023
• RevenuePLN 46.79M
• Revenue growth-67.5%
• Net incomePLN 586.00K
• Gross margin77.7%

Valuation Snapshot

Bullrun's latest valuation model marks Biomaxima as 85.4% overvalued; latest market cap is PLN 39.83M; P/E is 379.4.

About Biomaxima

BioMaxima S.A. produces and distributes microbiological media, reagents, and in vitro diagnostic equipment in Poland. It offers microbiology products, including ready to use media, such as plates, bottles, bags, and media in tubes; dehydrated media; agars and peptones; and supplements.

Frequently asked questions

Is Biomaxima overvalued or undervalued?

Bullrun's valuation model currently marks Biomaxima as 85.4% overvalued.

What is Biomaxima's market cap?

Biomaxima's market capitalization is PLN 39.83M.

What is Biomaxima's P/E ratio?

Biomaxima's price-to-earnings (P/E) ratio is 379.4.

What does Biomaxima do?

BioMaxima S.A. produces and distributes microbiological media, reagents, and in vitro diagnostic equipment in Poland. It offers microbiology products, including ready to use media, such as plates, bottles, bags, and media in tubes; dehydrated media; agars and peptones; and supplements.